Tsh metabolism in newborns.

Reading File

Finding Sources

Searching PubMed

TSH metabolism newborn thyroid function

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Reading File

I now have comprehensive content from two authoritative textbooks plus key diagrams. Here is the full answer:

TSH Metabolism in Newborns

1. Fetal Thyroid Development and the HPT Axis

The thyroid gland forms at the base of the tongue from endodermal cells as early as week 3 of gestation and descends to the pretracheal position by weeks 5-7. The hypothalamic-pituitary-thyroid (HPT) axis matures progressively:

Milestone	Gestational Age
TRH detectable in fetal CNS	~5 weeks
Thyroid descent to neck	~7 weeks
TRH in hypothalamus; TSH in pituitary/serum	~10-14 weeks
Fetal thyroid functional (iodide trapping, T4 synthesis)	~12 weeks
Hypothalamic-portal system active; fetal TSH and T4 begin rising	~18-20 weeks
Fetal T3 becomes significant	~30 weeks onward

Before ~16 weeks, the fetus is entirely dependent on maternal thyroid hormone (T4). Maternal TRH does not significantly cross the placenta, and TSH does not cross the placenta at all.

Changes in fetal thyroid function during gestation - Tietz Textbook of Laboratory Medicine, 7th Ed.

After 20 weeks, T4 steadily rises from ~2 µg/dL to adult levels of ~10 µg/dL at term, driven by pituitary TSH. Importantly, the rising T4 has minimal negative feedback on fetal TSH because the HPT axis remains immature and does not fully mature until 1-2 months after birth.

2. Fetal T3 and the Role of Deiodinases

The fetus maintains a high rT3 (reverse T3), low T3 environment deliberately:

Type 3 deiodinase (D3) dominates in fetal tissues and the placenta - it inactivates T4 to rT3 (rather than to active T3). This protects the fetus from premature exposure to biologically active T3.
Because of the high D3:D1 ratio, fetal serum T3 is negligible until ~30 weeks.
Near term, increasing D1 activity allows rising T3 levels (up to ~50 ng/dL), paralleled by a progressive decline in rT3.
Approximately 30-50% of T4 in cord blood is maternally derived, even at term.

3. The Postnatal TSH Surge - The Key Event

At birth, exposure to the cold extrauterine environment triggers a massive and rapid TRH surge from the hypothalamus, which drives an acute TSH release from the pituitary:

TSH peaks at ~30 minutes after birth (the "neonatal TSH surge")
This is the largest TSH rise seen at any point in human life
By 2-3 days, TSH falls back toward adult levels under T3/T4 negative-feedback inhibition

Thyroid hormone concentrations in the first 5 days after birth

Concentrations of thyroid hormones for 5 days after birth - Tietz Textbook of Laboratory Medicine, 7th Ed.

Downstream effects of the TSH surge:

TSH stimulates the thyroid gland to massively increase T4 and T3 secretion
T3 and T4 peak at ~24 hours after delivery
The disproportionately greater rise in T3 vs T4 in the first 24 hours reflects acutely increased conversion of T4 → T3 via maturation of type I deiodinase (D1)
T4 and T3 then gradually decline to stable adult-range concentrations by 4-6 weeks
Transient hyperthyroxinemia can also be triggered by neonatal cooling and may represent a thermogenic adaptation to extrauterine life

4. The HPT Axis in Prematurity

In premature neonates, the HPT axis is immature and the physiological TSH surge is dramatically lower or absent:

FT4 and FT3 levels are low despite "normal" TSH levels
May take 3-8 weeks after birth to achieve levels similar to term infants
Transient hypothalamic hypothyroidism of prematurity occurs in up to 50% of infants born before 28 weeks
It can be difficult to distinguish from true central hypothyroidism
Transient hypothyroxinemia in premature infants is associated with cognitive and neurological delays, but optimal treatment targets are not yet established

5. Clinical Relevance - Newborn Screening

Because TSH surges after birth, the timing of neonatal screening matters:

Screening is ideally done at 2-4 days of age in term infants (after the physiological TSH surge has resolved)
Within 7 days for preterm infants
TSH-first strategy: most common - elevated TSH triggers reflex FT4
Combined TSH + FT4: detects central hypothyroidism (low FT4 with normal or low TSH), thyroid hormone resistance, and conditions causing delayed TSH elevation
Screening with TSH alone misses central hypothyroidism (1 in 25,000-50,000 newborns)

Congenital hypothyroidism (CH) now has an estimated incidence of 1 in 2,000-4,000 newborns (higher than the historical estimate of 1 in 7,000, due to lower TSH cut-offs). If levothyroxine is started within the first 2 weeks of life, mental retardation is preventable in over 90% of affected children. - Tietz Textbook of Laboratory Medicine, 7th Ed.; Creasy & Resnik's Maternal-Fetal Medicine, 8th Ed.

Summary Table

Phase	TSH	T4	T3	Key Mechanism
<16 wks gestation	Low	Low (maternal)	Very low	Fetus dependent on maternal T4
16-40 wks	Gradually rising	Rising (2→10 µg/dL)	Low (D3 dominates → rT3)	Fetal HPT axis maturing
Birth (~30 min)	Massive surge (peak)	Rising	Rising	Cold-induced TRH release
Day 1 (~24 hrs)	Falling	Peak	Peak	TSH-driven secretion + D1 maturation (T4→T3)
Days 2-3	Returns to normal	Plateaus then falls	Plateaus then falls	T3/T4 negative feedback
Weeks 4-6	Adult levels	Adult levels	Adult levels	HPT axis fully mature

Recent evidence note: A 2025 systematic review/meta-analysis (PMID 39954784) found that delivery mode influences neonatal TSH levels - vaginal delivery is associated with a more robust TSH surge compared to elective caesarean section, consistent with the cold-stress and catecholamine-driven mechanism of the postnatal surge.

All i need to know about migraine. From incidence among people of various age groups, pathophysiology, classification, clinical presentation, risk factors, triggers, investigations, management, prognosis

Reading File

Finding Sources

Searching PubMed

migraine pathophysiology treatment guidelines

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Reading File

That covers everything you asked for. Here is a brief orientation to the answer above:

What was covered:

Epidemiology - 12% 1-year global prevalence, peak in the 4th decade, 3:1 F:M ratio after puberty, childhood equivalents, chronification rates
Pathophysiology - The modern neurovascular model: cortical spreading depression (CSD) as the electrophysiological substrate of aura; trigeminovascular activation and neurogenic inflammation; the central role of CGRP and 5-HT; the migraine generator debate (hypothalamus + dorsal pons); central sensitization and allodynia; why the old "vascular theory" is obsolete
Classification - Full ICHD-3 spectrum: migraine without aura, with aura (visual/sensory/language/motor), chronic, hemiplegic, basilar/brainstem aura, retinal, status migrainosus, migrainous infarction, childhood equivalents; diagnostic criteria
Clinical presentation - All four phases in detail: prodrome, aura (the "marching" sensory/visual/language phenomena and how to distinguish them from TIA or seizure), headache phase, postdrome
Risk factors - Genetics (FHM genes, GWAS loci), sex, age, obesity, mood disorders, medication overuse, hormonal factors
Triggers - Stress, hormones, sleep, diet, sensory stimuli, weather, medications - and why susceptibility fluctuates daily
Investigations - Primarily clinical; red flags and when to image (MRI vs. CT) or perform LP; ESR/CRP, TSH
Management - Non-pharmacological; acute treatment stratified by severity (analgesics → triptans → lasmiditan/gepants → DHE/ergots → ED protocols → status migrainosus); preventive treatment (beta-blockers, antiepileptics, TCAs; CGRP monoclonal antibodies; botulinum toxin A for chronic migraine; gepants); special populations
Prognosis - Fluctuating lifelong course, improvement post-menopause, risk of chronification, MOH, rare migrainous infarction risk

This is a shared conversation. Sign in to Orris to start your own chat.